ROE
-42.5%
ROE -42.5% is below the quality threshold; compare the multi-year trend before calling it structural.
NASDAQ · Healthcare · Large Cap · Mkt cap $9.0B · Vol 8.18M
$84.95
▲ +0.00% today
Live · market · updated 9:24:20 PM
Day $84.92–$85.01 · 52w $32.30–$85.01
Research Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Source: Yahoo Finance — Crinetics Pharmaceuticals, Inc. company profileCompany website
Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.
Weighted 13-factor score / 100
Crinetics Pharmaceuticals, Inc. scores 33/100 on the DeepScreen quality-and-value model. Growth is running near 2336.3% with a PEG of 4.76, ROCE of -51.4% and debt/equity at 0.04x. Valuation, leverage or returns are stretched relative to what the business currently earns.
Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Target price, trim level & stop-loss is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
The 33/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.
Conservative balance sheet. Weighted contribution: 8.6 points.
Very low structural debt. Weighted contribution: 6.3 points.
Full reinvestment — no dividend. Weighted contribution: 2.9 points.
Typical for the sector. Weighted contribution: 3.7 points.
Below cost of capital risk. Weighted contribution: 0.6 points.
Low for the sector. Weighted contribution: 0.4 points.
Weak. Weighted contribution: 0.5 points.
Priced for exceptional growth. Weighted contribution: 0.3 points.
Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.
Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.
Provider-reported period-over-period growth
Provider-reported period-over-period growth
Return on equity
Return on capital employed
Net income as a share of revenue
Debt relative to shareholder equity
Latest provider figure
Cash $1.21B · Debt $47.2M
Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.
Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.
Latest provider free cash flow is -248,761,632. Review working capital, capex and operating cash generation.
Signals are intended to highlight questions for research, not replace company filings or independent review.
Industry match: Biotechnology. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.
Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.
DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
3/83
3 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Low distortion risk0.84
Accrual-quality check only: operating cash flow is 84% of reported net profit. Below 80% means profits aren't fully backed by cash.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
P/E Ratio (TTM)
Modeled44.3x
Expensive — priced for high growth
Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.
PEG Ratio
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
P/S Ratio
Live213.80x
Rich sales multiple
Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.
P/B Ratio
Live7.54x
Typical for the sector
Price versus net asset value. Asset-light businesses like this one carry most of their value in people and IP, not machinery or property, so P/B runs structurally high here — not a red flag by itself. Weigh P/E and ROE more heavily instead.
EV/Revenue
LivePro
Advanced ratio · DeepScreen Pro
Pro
EV/EBITDA
LivePro
Advanced ratio · DeepScreen Pro
Pro
ROE
Live-42.5%
Weak
Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.
ROA
Modeled-40.8%
Low for the sector
Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.
ROCE
Modeled-51.4%
Below cost of capital risk
Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.
Debt / Equity
Live0.04x
Conservative balance sheet
Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.
LT Debt / Equity
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
Payout Ratio
Live0%
Full reinvestment — no dividend
Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.
Operating Leverage
Modeled3.13x
Profits amplify — both ways
How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.
DCF & Graham intrinsic value calculators is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.
Loading live headlines…
Review the scoring factors, underlying data and limitations before comparing companies.
Read the methodology